Get Taysha Gene Therapies alerts:Several other brokerages have also recently commented on TSHA. Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. As a group, research analysts forecast that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year. Taysha Gene Therapies Company Profile(Get Free Report)Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. Recommended StoriesReceive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.